PP
TBRA

Paloma Partners’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

Paloma Partners’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-25,224
Closed -$435K – 2181
2015
Q2 		$435K Buy
+25,224
New +$369K 0.01% 1162

Other funds holding TBRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Paloma Partners's TBRA Position: Q3 2015 in Review

Paloma Partners sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q3 2015, closing a stake of 25,224 shares — an estimated $435K sold.

Paloma Partners first reported a position in TBRA in Q2 2015 and held it in 1 quarter. The position peaked at $435K in Q2 2015. 49 funds tracked by Wall St. Rank hold TBRA as of Q3 2015.

  • Paloma Partners reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Paloma Partners sold 25,224 Tobira Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $435K.
  • Paloma Partners first reported a position in Tobira Therapeutics, Inc. Common Stock in Q2 2015 and held it in 1 quarter.
  • Paloma Partners's Tobira Therapeutics, Inc. Common Stock position peaked at $435K in Q2 2015.
  • 49 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Paloma Partners's 13F filing for Q3 2015, filed 16 Nov 2015.